Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bayer
With
GlaxoSmithKline
Schering-Plough
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Males 18 years-of-age or older.
Stable, heterosexual relationship for at least 6 months.
A history of erectile dysfunction (ED) for at least 6 months
You may not be if
Any underlying cardiovascular condition, including unstable angina pectoris
History of myocardial infarction, stroke or life-threatening arrhythmia within 6 months prior to visit 1
Uncontrolled atrial fibrillation / flutter at screening
History of congenital QT prolongation
History of surgical prostatectomy due to prostate cancer
Hereditary degenerative retinal disorders
History of loss of vision because of NAION (Non-arteritic anterior ischemic optic neuropathy), temporary or permanent loss of vision
Presence of penile anatomical abnormalities
Spinal cord injury
Resting or postural hypotension or hypertension
Subjects who are taking nitrates or nitric oxide donors, androgens, anti-androgens, alpha-blockers, HIV (Human immunodeficiency virus) protease inhibitors, itraconazole or ketoconazole, and clarithromycin and erythromycin.
Subjects taking medication known to prolong QT interval, such as Type Ia and Type 3 anti-arrhythmics.
Subjects who have been confirmed with phenylketonuria (PKU).
Use of any treatment for ED within 7 days of Visit 1.
Clareo Health | Vardenafil Orodispersible Tablet (ODT) Versus Placebo in Males With Erectile Dysfunction, 50% of Whom Are to be 65 Years or Older.
